The stock has a 36-month beta value of 0.20. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QLGN is 0.69M, and at present, short sellers hold a 10.15% of that float. On April 01, 2025, the average trading volume of QLGN was 63.59K shares.
QLGN) stock’s latest price update
The stock price of Qualigen Therapeutics Inc (NASDAQ: QLGN) has surged by 1.65 when compared to previous closing price of 3.64, but the company has seen a 10.23% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-25 that New York, Nov. 25, 2024 (GLOBE NEWSWIRE) — Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations.
QLGN’s Market Performance
Qualigen Therapeutics Inc (QLGN) has experienced a 10.23% rise in stock performance for the past week, with a 19.35% rise in the past month, and a -13.35% drop in the past quarter. The volatility ratio for the week is 14.48%, and the volatility levels for the past 30 days are at 6.06% for QLGN. The simple moving average for the last 20 days is 13.29% for QLGN stock, with a simple moving average of -45.02% for the last 200 days.
QLGN Trading at 8.96% from the 50-Day Moving Average
After a stumble in the market that brought QLGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.43% of loss for the given period.
Volatility was left at 6.06%, however, over the last 30 days, the volatility rate increased by 14.48%, as shares surge +10.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.13% lower at present.
During the last 5 trading sessions, QLGN rose by +1.69%, which changed the moving average for the period of 200-days by -67.37% in comparison to the 20-day moving average, which settled at $3.25. In addition, Qualigen Therapeutics Inc saw -12.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for QLGN
The total capital return value is set at 3.13. Equity return is now at value -1656.23, with -234.45 for asset returns.
Based on Qualigen Therapeutics Inc (QLGN), the company’s capital structure generated -2.03 points at debt to capital in total, while cash flow to debt ratio is standing at -6.78. The debt to equity ratio resting at -0.67. The interest coverage ratio of the stock is -6.41.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at -0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.52.
Conclusion
To sum up, Qualigen Therapeutics Inc (QLGN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
